Despite trastuzumab plus chemotherapy being the standard treatment for patients with advanced metastatic HER2-positive GC, not all of these treatments are beneficial with an overall response rate of only 47% (5% complete response plus 42% partial response) [13]. This evidence concerns the gene ERBB2 and gastric cancer.